Breaking News

Astellas Adds Executives

May 5, 2014

Zeiher and Barrett to head Global Development and Medical Affairs

Bernhardt Zeiher, M.D. has been appointed executive vice president of Global Development at Astellas and Jeannette A. Barrett, Ph.D., has been named vice president and head of Medical Excellence, Global Medical Affairs.
Dr. Zeiher will be responsible for Global Development Operations and Global Clinical Pharmacology and Exploratory Development (GCPED), in addition to serving as therapeutic area head of Immunology, Infectious Disease, Transplant, Central Nervous System and Pain. He will continue to report to Dr. Sef Kurstjens, chief medical officer and president of Global Development. Dr. Zeiher has more than 15 years of experience in the pharma industry. Most recently he was vice president of the inflammation/immunology therapeutic area at Pfizer.

Dr. Barrett will be responsible for supporting medical affairs activities globally and providing the tools, processes, systems and infrastructure to ensure transparency, operational consistency, limit risk and improve compliance. Dr. Barrett will report to Dr. Charlotte Kremer, senior vice president and head, Global Medical Affairs. Dr. Barrett has more than 20 years of experience in the areas of medical affairs, regulatory affairs and drug safety having held leadership roles at several global pharmaceutical companies, including Pfizer, where she spent 16 years.
"Both Bernie and Jeannette's global experience, along with their pharmaceutical and clinical knowledge, make them perfect fits for Astellas," said Kurstjens. "We are delighted to be promoting Bernie and bringing Jeannette on to the Astellas team to further our mission of bringing important treatment options to patients."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important